Keyword: Ocrevus

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.

Genentech has launched its first consumer campaign for multiple sclerosis drug Ocrevus, with emphasis on a particular cohort of patients: millennials.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact."

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

A post hoc analysis found 75% of patients showed no increase in disability five years after treatment with Mavenclad.

Patients on Ocrevus saw their blood neurofilament light chain level lowered to a healthy donor range in phase 3 studies, Roche said.

Roche is appealing a U.S. federal court decision, aiming to shove Amgen's copycats to Avastin and Herceptin off the U.S. market.

Reversing an earlier decision, England's drug-price watchdog approved Roche's superstar Ocrevus to treat primary progressive MS.